Gladstone-UCSF Institute of Genomic Immunology Seminar
Stefani Spranger, PhD
The Spranger Laboratory is working to understand how immune cells are impacted by cancer cells, and particularly focuses on when the immune system fails to recognize and eliminate abnormal cells. By understanding these basic immunological mechanisms, the group aims to identify new therapeutic targets, which will engage the immune system to provide durable responses to cancer. A general focus of the laboratory is on understanding how the cytotoxic T cell activation in the lymph node affects the quality and durability of the anti-tumor T cell response. Understanding the factors required to induce a systemic and long-lasting anti-tumor immune response will enable the lab to fight and prevent metastatic cancer spread.
Stefani Spranger is an associate professor of Biology at MIT. She received her bachelors and Master's degrees from the Ludwig-Maximilians University in Munich. She received her PhD in 2011 from the Helmholtz-Zentrum Munich Institute for Molecular Immunology, where she conducted her doctoral work under the supervision of Professor Dolores J. Schendel. Spranger completed her postdoctoral training at the University of Chicago in the laboratory of Professor Thomas F. Gajewski. During this period, she was supported by a German Research Foundation postdoctoral fellowship and subsequently received the Cancer Research Institute's Irvington Postdoctoral Fellowship. Spranger is a Scholar of the William Guy Forbeck Research Foundation, a Pew-Stewart Scholar for Cancer Research, and was elected to the Board of Directors of the Society for Immunotherapy of Cancer in 2019. Spranger is a co-founder of Danger Bio. While she is a member of the Scientific Advisory Board of Arcus Biosciences, Danger Bio, and Prox Bio, she also acts as an advisor to Dragonfly, Merck, Abbvie, and Takeda.
Details
Dates
February 11, 2025Time
10:00-11:00am PSTLocation
Mahley Auditorium & OnlineAudience
Gladstone and UCSFContact(s)
The Gladstone-UCSF Institute of Genomic Immunology Seminar Series showcases speakers at the intersection of genomic technology and immunology research with an aim to engineer the human immune system for therapeutic benefit. Speakers span technology development, synthetic biology, bioengineering, and the development and clinical application of immunotherapy. These talks are open to the Gladstone and UCSF communities.
Diversity, Equity, and Inclusion
At Gladstone, we are committed to providing events and professional development activities that resonate with our community’s diverse members. Our goal is to develop creative programming that encompasses a wide variety of ideas and perspectives to inspire, educate, and engage with everyone within our walls.
We want to effect positive change through our events and activities by providing a platform for discussions on important topics related to increasing diversity and inclusiveness in the sciences.